- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Processa Pharmaceuticals Inc (PCSA)
Processa Pharmaceuticals Inc stock price live, this page displays NASDAQ PCSA stock exchange data. View the PCSA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Processa Pharmaceuticals Inc real time stock price chart below.
What Is the Processa Pharmaceuticals Inc Stock Price Today?
The Processa Pharmaceuticals Inc stock price today is 1.4200.
What Is the Stock Symbol for Processa Pharmaceuticals Inc?
The stock symbol for Processa Pharmaceuticals Inc is "PCSA."
What Stock Exchange Does Processa Pharmaceuticals Inc Trade On?
Processa Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Processa Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Processa Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PCSA quote. (ISIN: US74275C4033)
What Is the Processa Pharmaceuticals Inc Stock Price Today?
The Processa Pharmaceuticals Inc stock price today is 1.4200.
What Is the Stock Symbol for Processa Pharmaceuticals Inc?
The stock symbol for Processa Pharmaceuticals Inc is "PCSA."
What Stock Exchange Does Processa Pharmaceuticals Inc Trade On?
Processa Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Processa Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Processa Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PCSA quote. (ISIN: US74275C4033)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.4100
1.5300
52 wk Range
1.4100
11.0800
Trading near 52-week Low
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.41001.5300
52 wk Range
1.410011.0800
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PCSA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock has taken a big hit over the last week
Form 8K Processa Pharmaceuticals Inc For: 11 August- Investing.com
Form 4 Processa Pharmaceuticals Inc For: 30 July- Investing.com
Form 8K Processa Pharmaceuticals Inc For: 14 August- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Earnings
Latest Release
Aug 14, 2026
EPS / Forecast
-1.19 / -0.05
Revenue / Forecast
-- / --
Compare PCSA to Peers and Sector
Metrics to compare | PCSA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPCSAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.4x | −3.6x | −0.3x | |
PEG Ratio | 0.00 | −0.22 | 0.00 | |
Price/Book | −15.0x | 0.8x | 2.6x | |
Price / LTM Sales | - | 1.6x | 3.0x | |
Upside (Analyst Target) | - | 93.8% | 57.9% | |
Fair Value Upside | Unlock | 21.7% | 7.6% | Unlock |
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited. Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Processa Pharmaceuticals (PCSA) Stock Price Today?
The Processa Pharmaceuticals stock price today is 1.4200 USD.
What Stock Exchange Does Processa Pharmaceuticals Trade On?
Processa Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Processa Pharmaceuticals?
The stock symbol for Processa Pharmaceuticals is "PCSA."
What Is the Processa Pharmaceuticals Market Cap?
As of today, Processa Pharmaceuticals market cap is 4.7600M USD.
What Is Processa Pharmaceuticals's Earnings Per Share (TTM)?
The Processa Pharmaceuticals EPS (TTM) is -5.5949.
From a Technical Analysis Perspective, Is PCSA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Processa Pharmaceuticals Stock Split?
Processa Pharmaceuticals has split 4 times.
How Many Employees Does Processa Pharmaceuticals Have?
Processa Pharmaceuticals has 12 employees.
What is the current trading status of Processa Pharmaceuticals (PCSA)?
As of Oct 08, 2026, Processa Pharmaceuticals (PCSA) is trading at a price of 1.4200 USD, with a previous close of 1.4200 USD. The stock has fluctuated within a day range of 1.4100 USD to 1.5300 USD, while its 52-week range spans from 1.4100 USD to 11.0800 USD.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.